Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.66 |
| ▸ | SELP | P16109 | 2/20 | 0.60 |
| ▸ | SELL | P14151 | 1/20 | 0.60 |
| ▸ | MAG | P20916 | 9/20 | 0.58 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.48 |
| ▸ | SELE | P16581 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393136 | 1.00 | SIGLEC7 (0.66) | SIGLEC7SELPSELLMAGNANP | |
| SCHEMBL29355980 | 1.00 | SIGLEC7 (0.66) | SIGLEC7SELPSELLMAGNANP | |
| SCHEMBL30439275 | 0.96 | SIGLEC7 (0.62) | SIGLEC7SELPSELLMAGNANP | |
| SCHEMBL30439269 | 0.96 | SIGLEC7 (0.62) | SIGLEC7SELPSELLMAGNANP | |
| SCHEMBL29356627 | 0.95 | SELP (0.62) | SIGLEC7SELPSELLMAGNANP | |
| SCHEMBL29396615 | 0.95 | SELP (0.62) | SIGLEC7SELPSELLMAGNANP | |
| SCHEMBL17300130 | 0.95 | SELP (0.62) | SIGLEC7SELPSELLMAGNANP | |
| SCHEMBL31716489 | 0.93 | SIGLEC7 (0.70) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL29615820 | 0.92 | SIGLEC7 (0.71) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL29378134 | 0.92 | SIGLEC7 (0.76) | SIGLEC7SELPSELLMAGSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651963-A1 | PURIFICATION OF AN OLIGOSACCHARIDE OR OLIGOSACCHARIDE MIXTURE | Inbiose N.V. (BE) | 2025-11-26 | — | — | EP | claimed |
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2024-09-12 | — | — | US | claimed |
| WO-2024153788-A1 | PURIFICATION OF AN OLIGOSACCHARIDE OR OLIGOSACCHARIDE MIXTURE | INBIOSE N.V. (BE) | 2024-07-25 | — | — | WO | claimed |
| US-20260132407-A1 | VIVO SYNTHESIS OF SIALYLATED COMPOUNDS | INBIOSE N V (BE) | 2026-05-14 | — | — | US | disclosed |
| EP-4731778-A2 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | Inbiose N.V. (BE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4702138-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | Inbiose N.V. (BE) | 2026-03-04 | — | — | EP | disclosed |
| EP-4662224-A1 | PRODUCTION OF A SACCHARIDE BY A CELL WITH REDUCED SYNTHESIS OF LACTOBIONIC ACID | Inbiose N.V. (BE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4662305-A1 | PRODUCTION OF A DISACCHARIDE AND/OR MILK OLIGOSACCHARIDE BY A CELL WITH REDUCED SYNTHESIS OF UDP-GLCNAC | Inbiose N.V. (BE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4651963-A1 | PURIFICATION OF AN OLIGOSACCHARIDE OR OLIGOSACCHARIDE MIXTURE | Inbiose N.V. (BE) | 2025-11-26 | — | — | EP | disclosed |
| US-12378589-B2 | In vivo synthesis of sialylated compounds | INBIOSE N.V. (BE) | 2025-08-05 | — | — | US | disclosed |
| WO-2025088102-A1 | PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE COMPRISING GAL-β1,3-[NEU5AC-A2,6]-HEXNAC-R | INBIOSE N.V. (BE) | 2025-05-01 | — | — | WO | disclosed |
| EP-4103727-A2 | PRODUCTION OF GLYCOSYLATED PRODUCT IN HOST CELLS | Inbiose N.V. (BE) | 2022-12-21 | — | — | EP | disclosed |
| EP-4103710-A1 | VIABLE BACTERIAL HOST CELL | Inbiose N.V. (BE) | 2022-12-21 | — | — | EP | disclosed |
| EP-4103726-A1 | KDO-FREE PRODUCTION HOSTS FOR OLIGOSACCHARIDE SYNTHESIS | Inbiose N.V. (BE) | 2022-12-21 | — | — | EP | disclosed |
| US-20220396761-A1 | VIABLE BACTERIAL HOST CELL | INBIOSE N.V. (BE) | 2022-12-15 | — | — | US | disclosed |
| EP-4077678-A1 | PRODUCTION OF SIALYLATED OLIGOSACCHARIDE IN HOST CELLS | Inbiose N.V. (BE) | 2022-10-26 | — | — | EP | disclosed |
| CN-115135769-A | KDO-free production hosts for oligosaccharide synthesis | 因比奥斯公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20220298530-A1 | Optimal Chromosomal Insertion Loci | INBIOSE N.V. (BE) | 2022-09-22 | — | — | US | disclosed |
| US-20220251619-A1 | Method of Sialylating a Protein | THE UNIVERSITY OF MANCHESTER (GB) | 2022-08-11 | — | — | US | disclosed |
| EP-3980542-A1 | OPTIMAL CHROMOSOMAL INSERTION LOCI | Inbiose N.V. (BE) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132407-A1 | VIVO SYNTHESIS OF SIALYLATED COMPOUNDS | NANS, NANP, NAPRT | SIGLEC7 166/4885SELP 371/4885SELL 607/4885 |
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | SGMS1, UGCG, SGMS2 | SIGLEC7 64/4885SELP 241/4885SELL 336/4885 |
| US-20220251619-A1 | Method of Sialylating a Protein | ST6GAL1, NEU2, NEU1 | SIGLEC7 22/4885SELP 128/4885SELL 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.